Pricing Log in Create free account
Saturday 17 October 2026 Export ERNA’s income statement to Excel — free account

Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Eterna Therapeutics Inc. (ERNA) Business Profile

Updated before January 2025

Company Overview

Eterna Therapeutics Inc. (ERNA) is a biotechnology company dedicated to advancing transformative therapies through innovative gene-editing technologies. Founded in [insert founding year], the company is headquartered in [insert location]. Eterna Therapeutics was established with the mission of addressing unmet medical needs by leveraging cutting-edge science to develop novel treatments for a variety of diseases. The company is led by a team of seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and healthcare. Key leadership includes [insert CEO name], who serves as the Chief Executive Officer, and [insert other key leadership roles and names].

Core Business Segments

Eterna Therapeutics operates across several core business segments, focusing on the development and commercialization of gene-editing technologies and related therapies. These segments include:

Gene-Editing Platforms

Eterna specializes in proprietary gene-editing platforms designed to address genetic disorders. These platforms include:

  • CRISPR-Based Technologies: Advanced tools for precise gene editing to correct genetic mutations.
  • Base Editing: A next-generation approach to modify specific DNA bases without introducing double-strand breaks.

Therapeutic Development

The company is actively developing therapies targeting a range of diseases, including:

  • Oncology: Gene-editing solutions aimed at treating various forms of cancer.
  • Rare Genetic Disorders: Therapies designed to address conditions caused by single-gene mutations.
  • Immunological Diseases: Innovations to modulate immune responses for autoimmune and inflammatory conditions.

Research and Development Services

Eterna offers R&D services to academic institutions and pharmaceutical companies, including:

  • Custom gene-editing solutions.
  • Preclinical and clinical trial support.

Business Model

Eterna Therapeutics employs a hybrid business model that integrates product development, service offerings, and strategic partnerships. The company generates revenue through:

  • Product Sales: Licensing its proprietary gene-editing platforms to other biotech firms.
  • Collaborations and Partnerships: Joint ventures with pharmaceutical companies to co-develop therapies.
  • Service Contracts: Providing R&D services to external organizations.

This diversified approach allows Eterna to maintain a steady revenue stream while investing in long-term innovation.

Strategic Direction

Eterna Therapeutics is focused on expanding its portfolio of gene-editing technologies and therapies. Key strategic initiatives include:

  • Pipeline Expansion: Developing new therapies for additional disease areas, including neurodegenerative disorders and metabolic diseases.
  • Global Reach: Establishing partnerships with international organizations to expand its market presence.
  • Sustainability Goals: Implementing eco-friendly practices in its research and manufacturing processes.
  • Regulatory Approvals: Accelerating the approval process for its therapies by collaborating closely with regulatory agencies.

Competitive Landscape

Eterna operates in a highly competitive biotechnology sector. Key competitors include:

  • Editas Medicine: A leader in CRISPR-based gene-editing technologies.
  • Intellia Therapeutics: Known for its focus on in vivo gene-editing therapies.
  • CRISPR Therapeutics: A pioneer in developing CRISPR-based treatments for genetic diseases.
  • Beam Therapeutics: Specializes in base-editing technologies.

Despite the competition, Eterna differentiates itself through its proprietary platforms and focus on underserved therapeutic areas.

Risk Factors

Eterna Therapeutics faces several risks, including:

  • Regulatory Challenges: Delays in obtaining approvals for its therapies could impact timelines and revenue.
  • Market Dependence: Reliance on a limited number of products and services for revenue generation.
  • Supply Chain Disruptions: Potential delays in obtaining raw materials for research and manufacturing.
  • Technological Risks: Rapid advancements in gene-editing technologies could render Eterna’s platforms obsolete.

Recent Developments

Eterna has recently achieved significant milestones, including:

  • New Product Launches: Introduction of a next-generation base-editing platform.
  • Strategic Partnerships: Collaboration with [insert partner name] to co-develop therapies for rare diseases.
  • Clinical Trials: Initiation of Phase I trials for its lead oncology candidate.
  • Global Developments: Adaptation to supply chain challenges caused by the COVID-19 pandemic.

Investment Considerations

Strengths

  • Proprietary gene-editing platforms with broad applications.
  • Strong leadership team with extensive industry experience.
  • Diversified revenue streams through products, services, and partnerships.
  • Focus on high-growth therapeutic areas such as oncology and rare diseases.

Risks

  • High R&D costs and long timelines for therapy development.
  • Dependence on regulatory approvals for revenue generation.
  • Intense competition in the biotechnology sector.

Conclusion

Eterna Therapeutics Inc. is well-positioned in the biotechnology market, with a strong focus on innovation and addressing unmet medical needs. The company’s proprietary gene-editing platforms and diversified business model provide a solid foundation for future growth. While challenges such as regulatory hurdles and competition exist, Eterna’s strategic initiatives and commitment to innovation make it a promising player in the industry.